PDCD1 and neoplasm: For example, AK112, also known as ivonescimab, is the first-in-class humanized IgG1 bispecific antibody that targets PD-1 and VEGFA by inhibiting PD-1-mediated immunosuppression and simultaneously blocking tumor angiogenesis in the TME (31).